Leukemia Research and Treatment / 2013 / Article / Tab 1

Clinical Study

Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?

Table 1


Patient demographics

Male, (%)59 (54)
Median BSA (range), m22.05 (1.36–2.84)

Diagnosis (%)

Follicular lymphoma70 (64)
Marginal zone lymphoma11 (10)
Unspecified low-grade lymphoma9 (8)
Mantle cell lymphoma10 (9)
CLL/SLL6 (5.5)
Mucosa-associated lymphoid tissue3 (2.8)

Baseline laboratory parametersk/ L (range)

Median lymphocyte count1.24 (0.04–8.21)
Median WBC5.38 (1.34–13.07)

Premedications

Acetaminophen99%
Diphenhydramine75%
Cetirizine23%
Corticosteroids8.8%
Rituximab
 Median dose, mg750 (410–1090)
 Median no. doses6 (1–20)
 Mean infusion time, min90 (85–97)

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.